Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

The anti-inflammatory Sotyktu, the heart drug Camzyos, and the anemia treatment Reblozyl — three drugs on which ... sellers — the blood-thinner Eliquis and cancer immunotherapy Opdivo — will lose ...

Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...